Investor Relations

Latest Financial Results

Q3 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending June 30, 2023

Report Links

Company Overview

Kintara Therapeutics is a biopharmaceutical company focused on the development and commercialization of new solid tumor cancer therapies.

REM-001 Therapy consists of three parts, a laser light source, a light delivery device and the drug REM-001 (collectively, REM-001 Therapy). REM-001 is a second generation photosensitizer drug that has undergone late stage clinical development, and which we believe possesses multiple advantages over earlier generation PDT compounds. Our lead indication for REM-001 Therapy is unresectable cutaneous metastatic breast cancer (CMBC), a disease that may affect individuals with advanced breast cancer and for which effective treatment options are limited. For this and similar cutaneous applications, the light delivery device is a simple and easy to use fiber optic wand that the physician employs to directly illuminate the tumor with light.

Stock Snapshot

IR Contacts


Kintara Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 150
San Diego, CA 92121
United States
T: 858-350-4364

Investor Relations

T: 858-350-4364

Transfer Agent

Mountain Share Transfer, LLC
2030 Powers Ferry Road SE
Suite #212
Atlanta, Ga. 30339
United States
T: 404-474-3110
F: 404-816-8830